Source: Annual Congress 2013 –Lung infections: a clinical point of view



Rating:

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Shtepa (Dnipropetrovsk, Ukraine). Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI). Eur Respir J 2013; 42: Suppl. 57, 2211

Member's Comments

No comment yet.

Related content which might interest you: The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)? Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Procalcitonin (PCT) as a diagnostic tool in lower respiratory tract infections (LRTI) and TB Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Can Neutrophil/lymphocyte Ratio, C-reactive protein (CRP) and Procalcitonin predict the hospitalization time in patients with lower tract respiratory infections ? Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007